 |
144 Diseases |  |
5 Trials |
|
5 Trials |  |
837 News |  |
| «12345678 |
- |||| imetelstat (JNJ-63935937) / Geron
Clinical: MDS3001: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Mar 4, 2016
P3, N=200, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Mar 2018 --> Jun 2018
- |||||| imetelstat (GRN163L) / Geron
Enrollment open: IMerge: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Dec 5, 2015
P3, N=200, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Mar 2018 --> Jun 2018 Not yet recruiting --> Recruiting
- ||| imetelstat (JNJ-63935937) / Geron
Enrollment closed: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (clinicaltrials.gov) - Nov 15, 2015
P2, N=81, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| imetelstat (GRN163L) / Geron
New P3 trial: IMerge: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Nov 8, 2015
P3, N=200, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- Herceptin (trastuzumab) / Roche
Trial completion: A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer (clinicaltrials.gov) - Oct 27, 2015
P1, N=10, Completed, Sponsor: Indiana University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| imetelstat (JNJ-63935937) / Geron
Enrollment open, Enrollment change: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (clinicaltrials.gov) - Sep 25, 2015
P2, N=80, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Recruiting | N=56 --> 80
- imetelstat (GRN163L) / Geron
Enrollment open, Trial primary completion date: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor (clinicaltrials.gov) - Jul 16, 2015
P2, N=200, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Recruiting | N=56 --> 80 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2018 --> Mar 2017
- ||| imetelstat (JNJ-63935937) / Geron
Phase classification, Enrollment change, Trial primary completion date: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (clinicaltrials.gov) - Jun 20, 2015
P2, N=56, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2018 --> Mar 2017 Phase classification: P=N/A --> P2 | N=80 --> 56 | Trial primary completion date: Sep 2015 --> Mar 2017
- ||||| imetelstat (GRN163L) / Geron
New P2 trial: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor (clinicaltrials.gov) - Apr 25, 2015
P2, N=200, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||| Rytelo (imetelstat) / Geron
Enrollment change: Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Apr 21, 2015
P2, N=116, Completed, Sponsor: Geron Corporation
Phase classification: P=N/A --> P2 | N=80 --> 56 | Trial primary completion date: Sep 2015 --> Mar 2017 N=96 --> 116
- | imetelstat (GRN163L) / Geron
Trial completion, Enrollment change, Trial primary completion date: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (clinicaltrials.gov) - Apr 21, 2015
P2, N=20, Completed, Sponsor: Geron Corporation
N=96 --> 116 Active, not recruiting --> Completed | N=40 --> 20 | Trial primary completion date: Jan 2014 --> Oct 2013
- | imetelstat (GRN163L) / Geron
Trial completion, Enrollment change: Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma (clinicaltrials.gov) - Mar 11, 2015
P2, N=13, Completed, Sponsor: Geron Corporation
Active, not recruiting --> Completed | N=40 --> 20 | Trial primary completion date: Jan 2014 --> Oct 2013 Active, not recruiting --> Completed | N=48 --> 13
- | imetelstat (GRN163L) / Geron
Enrollment closed: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (clinicaltrials.gov) - Nov 13, 2014
P2, N=40, Active, not recruiting, Sponsor: Geron Corporation
Active, not recruiting --> Completed | N=48 --> 13 Suspended --> Active, not recruiting
- imetelstat (GRN163L) / Geron
Enrollment closed, Enrollment change: Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (clinicaltrials.gov) - Oct 28, 2014
P2, N=43, Active, not recruiting, Sponsor: Pediatric Brain Tumor Consortium
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting | N=90 --> 43
- || imetelstat (JNJ-63935937) / Geron
Enrollment change, Trial primary completion date: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Geron Corporation
Recruiting --> Active, not recruiting | N=90 --> 43 N=40 --> 80 | Trial primary completion date: Jan 2015 --> Sep 2015
- imetelstat (GRN163L) / Geron
Trial primary completion date: Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma (clinicaltrials.gov) - Aug 15, 2014
P2, N=48, Active, not recruiting, Sponsor: Geron Corporation
N=40 --> 80 | Trial primary completion date: Jan 2015 --> Sep 2015 Trial primary completion date: Dec 2013 --> Dec 2014
- imetelstat (JNJ-63935937) / Geron
Trial primary completion date: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2013 --> Dec 2014 Trial primary completion date: Jan 2014 --> Jan 2015
- imetelstat (GRN163L) / Geron
Trial initiation date: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Jun 2, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Trial primary completion date: Jan 2014 --> Jan 2015 Initiation date: Jan 2014 --> Jun 2014
- imetelstat (GRN163L) / Geron
Trial suspension: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (clinicaltrials.gov) - Mar 23, 2014
P2, N=40, Suspended, Sponsor: Geron Corporation
Initiation date: Jan 2014 --> Jun 2014 Active, not recruiting --> Suspended
- imetelstat (GRN163L) / Geron
Trial withdrawal: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 6, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Active, not recruiting --> Suspended Not yet recruiting --> Withdrawn
- imetelstat (GRN163L) / Geron
Enrollment change: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 6, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Not yet recruiting --> Withdrawn N=110 --> 0
- imetelstat (GRN163L) / Geron
Enrollment open: Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=90, Recruiting, Sponsor: Pediatric Brain Tumor Consortium
N=110 --> 0 Suspended --> Recruiting
- ||| imetelstat (GRN163L) / Geron
Trial completion: Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies (clinicaltrials.gov) - Feb 17, 2014
P1, N=85, Completed, Sponsor: Geron Corporation
Suspended --> Recruiting Active, not recruiting --> Completed
- | imetelstat (GRN163L) / Geron
Trial completion: Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD) (clinicaltrials.gov) - Feb 17, 2014
P1, N=48, Completed, Sponsor: Geron Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- imetelstat (GRN163L) / Geron
Enrollment change: Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma (clinicaltrials.gov) - Jan 28, 2014
P1, N=34, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=45 --> 34
- | imetelstat (GRN163L) / Geron
Trial completion: Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma (clinicaltrials.gov) - Jan 28, 2014
P1, N=34, Completed, Sponsor: Children's Oncology Group
N=45 --> 34 Active, not recruiting --> Completed
- imetelstat (JNJ-63935937) / Geron
Enrollment change: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (clinicaltrials.gov) - Jan 27, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed N=29 --> 40
- imetelstat (JNJ-63935937) / Geron
Enrollment closed: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis (clinicaltrials.gov) - Jan 27, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: Mayo Clinic
N=29 --> 40 Recruiting --> Active, not recruiting
- imetelstat (GRN163L) / Geron
New P2 trial: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Dec 11, 2013
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
- imetelstat (GRN163L) / Geron
Trial withdrawal: Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma (clinicaltrials.gov) - Nov 24, 2013
P1, N=0, Withdrawn, Sponsor: NCIC Clinical Trials Group
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- imetelstat (GRN163L) / Geron
Enrollment change: Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma (clinicaltrials.gov) - Nov 24, 2013
P1, N=0, Withdrawn, Sponsor: NCIC Clinical Trials Group
Not yet recruiting --> Withdrawn N=18 --> 0
- |||| Rytelo (imetelstat) / Geron
Trial completion: Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Oct 9, 2013
P2, N=96, Completed, Sponsor: Geron Corporation
N=18 --> 0 Active, not recruiting --> Completed
- imetelstat (GRN163L) / Geron
New P1 trial: Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma (clinicaltrials.gov) - Aug 1, 2013
P1, N=0, Withdrawn, Sponsor: NCIC Clinical Trials Group
- | imetelstat (GRN163L) / Geron
Enrollment closed: Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma (clinicaltrials.gov) - Jul 22, 2013
P2, N=48, Active, not recruiting, Sponsor: Geron Corporation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | imetelstat (GRN163L) / Geron
New P2 trial: Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (clinicaltrials.gov) - Apr 18, 2013
P2, N=90, Recruiting, Sponsor: Pediatric Brain Tumor Consortium
- | imetelstat (GRN163L) / Geron
Enrollment change, Combination therapy, Metastases: A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 26, 2013
P1/2, N=24, Completed, Sponsor: Geron Corporation
Recruiting --> Active, not recruiting N=35 --> 24
- |||| imetelstat (GRN163L) / Geron
Trial completion, Combination therapy, Metastases: Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 26, 2013
P2, N=166, Completed, Sponsor: Geron Corporation
N=35 --> 24 Active, not recruiting --> Completed
- | imetelstat (GRN163L) / Geron
Trial completion, Combination therapy, Metastases: A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 26, 2013
P1/2, N=24, Completed, Sponsor: Geron Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- imetelstat (GRN163L) / Geron
Trial withdrawal: Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma (clinicaltrials.gov) - Nov 5, 2012
P1, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Herceptin (trastuzumab) / Roche
Enrollment change: A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer (clinicaltrials.gov) - Oct 9, 2012
P1, N=10, Active, not recruiting, Sponsor: Indiana University
Recruiting --> Withdrawn N=18 --> 10
- Herceptin (trastuzumab) / Roche
Enrollment closed: A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer (clinicaltrials.gov) - Oct 9, 2012
P1, N=10, Active, not recruiting, Sponsor: Indiana University
N=18 --> 10 Recruiting --> Active, not recruiting
- imetelstat (GRN163L) / Geron
New P1 trial: Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma (clinicaltrials.gov) - Mar 29, 2012
P1, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
- | imetelstat (GRN163L) / Geron
Trial completion, Combination therapy: Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma (clinicaltrials.gov) - Jan 23, 2012
P1, N=40, Completed, Sponsor: Geron Corporation
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | imetelstat (GRN163L) / Geron
Trial completion: Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma (clinicaltrials.gov) - Jan 23, 2012
P1, N=20, Completed, Sponsor: Geron Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | imetelstat (GRN163L) / Geron
Trial completion, Combination therapy, Metastases: Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer (clinicaltrials.gov) - Jan 23, 2012
P1, N=27, Completed, Sponsor: Geron Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed